Every 10-Q that USANA Health Sciences Inc (USNA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow USNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full USNA filings page.
USANA Health Sciences reported weaker results for the quarter ended July 4, 2026. Net sales were $223.3 million, down from $235.8 million, as Core Nutritional and Hiya both declined, partly offset by strong growth at Rise. Core Nutritional still represented about 84% of year-to-date sales, with approximately 384,000 active customers, down 8.1% year over year.
The company posted a net loss attributable to USANA of $21.4 million versus prior-year earnings of $9.7 million, or $(1.16) per diluted share compared with $0.52. Results were heavily affected by a non-cash goodwill impairment charge of $29.1 million in the Hiya reporting unit following lower-than-expected performance and reduced forecasts. Despite the loss, operating cash flow for the first six months was $33.1 million and cash and cash equivalents were $168.6 million, with no borrowings outstanding on the $75 million credit facility.
USANA Health Sciences reported Q1 2026 net sales of $250.2 million, essentially flat year over year as Core Nutritional and Hiya declines were offset by strong growth at Rise. Core Nutritional sales were $204.4 million, down 3.0%, while Hiya fell 13.3% to $32.2 million and Rise jumped 740.7% to $13.7 million on the Protein Pop rollout.
Consolidated gross margin slipped to 76.2% from 79.0%, pressured by lower‑margin Rise and production inefficiencies in Core Nutritional. Net earnings attributable to USANA declined to $7.5 million from $9.4 million, with diluted EPS at $0.41 versus $0.49, reflecting lower operating margin and a higher 55.0% effective tax rate. Core Nutritional active Customers decreased 12.0% to 404,000, while USANA ended the quarter with $162.8 million in cash and cash equivalents and $14.0 million drawn on a $75 million revolving credit facility.
USANA Health Sciences reported Q3 2025 net sales of $213.7 million, up 6.7% year over year, driven by the addition of the Hiya direct‑to‑consumer business ($30.8 million) and growth in “Other,” which offset declines in direct selling.
The quarter showed a net loss of $6.5 million versus earnings of $10.6 million a year ago. Management cites a sharp increase in the annualized effective tax rate to 65% and higher selling, general and administrative costs, including amortization of acquired intangibles and elevated marketing at Hiya. Gross margin was 77.2% (down 320 bps), reflecting Hiya’s lower gross margin mix and higher “Other.”
Direct selling net sales fell as active customers decreased to 388,000, with broad softness across Asia Pacific and Americas/Europe. Cash and cash equivalents were $145.3 million and there was no balance on the $75 million revolver at quarter‑end. Year to date, USANA repurchased 927,000 shares for $27.7 million, leaving $34.0 million authorized. As of October 31, 2025, shares outstanding were 18,280,857. Subsequently, the company initiated a cost alignment program with an expected $4.7 million one‑time Q4 charge.
USANA Health Sciences, Inc. (USNA) — Quarterly report (10-Q) for period ended June 28, 2025.
Key financials: Net sales were $235.8M for Q2 2025, up 10.8% y/y; six‑month net sales were $485.4M. Net earnings attributable to USANA were $9.7M for Q2 (Q2 2024: $10.4M) and $19.1M for six months (prior: $27.0M). Diluted EPS was $0.52 for the quarter and $1.01 for six months.
Material events and balance sheet highlights: the company completed a controlling acquisition of Hiya on December 23, 2024 for a final purchase price of $206,074, recognizing $127.3M of goodwill and $124.2M of intangibles (acquired). Cash and cash equivalents were $151.3M as of June 28, 2025 ($154.1M total cash, cash equivalents and restricted cash). Inventories increased to $83.3M. During the six months the company repurchased and retired 927 shares for $27.7M. A redeemable noncontrolling interest in Hiya totaled $54.5M. The Credit Facility provides up to $75.0M revolver capacity; outstanding balance was $0 at June 28, 2025.